摘要
目的评价射频消融(RFA)治疗TACE术后肝癌残余病灶的临床效果。方法回顾分析采用RFA治疗TACE术后残余病灶的原发性肝癌31例,及同期采用多次TACE治疗的原发性肝癌43例,分别称为联合治疗组和TACE组。对两组的疗效、无进展生存期(PFS)、总生存期(OS)及不良反应进行综合对比研究。结果联合治疗组的客观缓解率(87.1%)高于TACE组(65.1%),差异有统计学意义(P<0.05);联合治疗组的m PFS(19个月)及m OS(33个月)均高于TACE组(m PFS 14.5个月,m OS 29个月),差异有统计学意义(P<0.05)。结论射频消融对TACE术后残余病灶有较好的临床疗效,可延长患者的无进展生存期及总生存期。
Objective To evaluate the curative effect of radiofrequency ablation (RFA) for the treatment of hepatic residual lesions after transcatheter arterial chemoembolization (TACE). Methods RFA was employed to treat residual hepatic lesions in 31 patients with primary hepatocellular carcinoma (HCC) after TACE, regarded as combination therapy group. Other 43 HCC patients, who received multiple times of TACE over the same period, were collected as TACE group. The clinical data were retrospectively analyzed. The curative effect, progression-free survival (PFS), overall survival (OS) and adverse reactions were comprehensively compared between the two groups. Results The objective remission rate in the combination therapy group was 87.1%, which was significantly higher than 65.1% of the TACE group, the difference between the two groups was statistically significant (P〈0.05). The median PFS and median OS of the combination therapy group were 19.0 months and 33.0 months respectively, while the median PFS and median OS of the TACE group were 14.5 months and 29.0 months respectively; the differences between the two groups were statistically significant (P〈0.05). Conclusion For the treatment of residual HCC lesions after TACE, RFA has satisfactory clinical effect, it can prolong PFS and OS of the patients.
出处
《介入放射学杂志》
CSCD
北大核心
2016年第12期1097-1100,共4页
Journal of Interventional Radiology
基金
浙江省瑞安市科技局科研项目(Y2014017)
关键词
原发性肝癌
肝动脉化疗栓塞
射频消融
残余病灶
primary hepatocellular carcinoma
hepatic arterial chemoembolization
radiofrequency ablation
residual lesion